Keymed Biosciences hits near 3-month high on product revenue growth

By Reuters News

** Shares of Keymed Biosciences 2162.HK jump 12.5% to HK$85.7, their highest level since July 24

** Stock of biological therapies developer on course for biggest one-day pct rise since June 29 after three consecutive sessions of falls

** Keymed recorded about 660 million yuan ($98.63 million) in revenue from product Kangyueda during the first three quarters of 2026, up 227% y/y on support of national policies

** Kangyueda is the trade name of IL-4Rα monoclonal antibody stapokibart for treatment of inflammatory diseases

** China's National Medical Products Administration has approved marketing application for new indication of stapokibart for treatment of atopic dermatitis in adolescents

** YTD, stock up 58.2%, Hang Seng Biotech Index .HSBIO up 6.47%

($1 = 6.6918 Chinese yuan)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.